Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the safety and tolerability of denosumab
administration as measured by adverse events, immunogenicity, and safety laboratory
parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.